Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Weekly Repeated Intravenous Infusions in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2018
At a glance
- Drugs BI 836880 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 05 Jun 2018 Results (n=14) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results of PK/PD analysis from two phase I studies including this study presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 06 Feb 2018 Planned End Date changed from 12 Aug 2018 to 19 Feb 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History